首页/数据集/Average treatment cost for ADRs associated with IV-TZM or SC-TZM treatment (costs in USD 2017).

Average treatment cost for ADRs associated with IV-TZM or SC-TZM treatment (costs in USD 2017).

Figshare2020-02-05 更新2026-04-28 收录

数据链接：

https://figshare.com/articles/dataset/Average_treatment_cost_for_ADRs_associated_with_IV-TZM_or_SC-TZM_treatment_costs_in_USD_2017_/11810922 数据链接链接失效反馈

官方服务：

资源简介：

Average treatment cost for ADRs associated with IV-TZM or SC-TZM treatment (costs in USD 2017).

应用场景：

创建时间：

2020-02-05

药物经济学评估

卫生技术评估

Trata-se do repositório de versões do modelo completo de análise de custo-efetividade do Monlupiravir contra infecção de COVID-19 em pacientes idosos e imunossurpimidos elaborado pelo Núcleo de Avali

NIAID Data Ecosystem80

Crude and adjusted rate ratios of health care resource utilization among different 1LOT groups.

医疗资源利用分析

药物经济学评估

Crude and adjusted rate ratios of health care resource utilization among different 1LOT groups.

Figshare2021-05-26 更新30

Differences in healthcare resource utilization and direct medical costs of patients with rheumatoid arthritis (RA) before and after the use of multiple biologic agents-Switched.

药物经济学评估

类风湿关节炎治疗管理

Differences in healthcare resource utilization and direct medical costs of patients with rheumatoid arthritis (RA) before and after the use of multiple biologic agents-Switched.

Figshare2018-07-18 更新10

Cost-utility of enoxaparin compared with unfractionated heparin in unstable coronary artery disease

药物经济学评估

血管疾病治疗

BACKGROUND: Low molecular weight heparins hold several advantages over unfractionated heparin including convenience of administration. Enoxaparin is one such heparin licensed in the UK for use in unst

PubMed Central2001-10-15 更新30

Table 1_Efficacy and safety of antiviral treatments for symptomatic COVID-19 outpatients: network meta-analysis and budget impact analysis.docx

药物经济学评估

COVID-19治疗

IntroductionRemdesivir (RDV) and nirmatrelvir/ritonavir (NRM/RTV) are two antiviral agents for treating outpatient adults with mild to moderate symptomatic COVID-19 at high risk of developing a severe

NIAID Data Ecosystem10

Average treatment cost for ADRs associated with IV-TZM or SC-TZM treatment (costs in USD 2017).

资源简介：

相关数据集